TSW
CRL icon

Thompson Siegel & Walmsley’s Charles River Laboratories CRL Stock Holding History

Thompson Siegel & Walmsley’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-36,605
Closed -$5.73M – 410
2025
Q3 		$5.73M Sell
36,605
-3,688
-9% -$586K 0.09% 209
2025
Q2 		$6.11M Buy
+40,293
New +$5.37M 0.1% 190

Other funds holding CRL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Harris Associates
Harris Associates Chicago, Illinois $75.4B AUM 14.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

Thompson Siegel & Walmsley's CRL Position: Q4 2025 in Review

Thompson Siegel & Walmsley sold out of Charles River Laboratories (CRL) in Q4 2025, closing a stake of 36,605 shares — an estimated $5.73M sold.

Thompson Siegel & Walmsley first reported a position in CRL in Q2 2025 and held it in 2 quarters. The position peaked at $6.11M in Q2 2025. 582 funds tracked by Wall St. Rank hold CRL as of Q4 2025.

  • Thompson Siegel & Walmsley reported no remaining Charles River Laboratories position as of Q4 2025 after selling out during the quarter.
  • Thompson Siegel & Walmsley sold 36,605 Charles River Laboratories shares in Q4 2025, an estimated $5.73M.
  • Thompson Siegel & Walmsley first reported a position in Charles River Laboratories in Q2 2025 and held it in 2 quarters.
  • Thompson Siegel & Walmsley's Charles River Laboratories position peaked at $6.11M in Q2 2025.
  • 582 funds tracked by Wall St. Rank held Charles River Laboratories as of Q4 2025.

Based on Thompson Siegel & Walmsley's 13F filing for Q4 2025, filed 10 Feb 2026.